vaso occlusive crisis pipeline insight

DelveInsight’s, "Vaso-occlusive crises - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vaso-occlusive crises pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Vaso-occlusive crises Understanding

Vaso-occlusive crises: Overview

Vaso-occlusive crises (VOCs), also known as acute sickle cell pain crises, are the most common, painful complication of the disease and the main reason why patients seek medical care in hospitals. Vaso-occlusive events are driven by endothelium damage/dysfunction and inflammation, which can then lead to vascular damage. SCD patients’ erythrocytes have the propensity to change into crescent shapes with abnormal adhesive properties, which increase interactions with white blood cells, platelets, endothelial cells, and extracellular matrix proteins. All these abnormal interactions accelerate the development of clinical vasculopathy and promote cerebrovascular and pulmonary vascular diseases. VOC significantly affects patients’ quality of life and often requires emergency care. Several diary studies of SCD patients have reported high rates of pain as well as an intense severity of pain during study days. VOC is the leading cause of hospitalization among SCD patients, and health care utilization (HRU) among SCD patients remains high due to patients’ difficulty with acute pain management and the lack of new effective therapies.

 

"Vaso-occlusive crises - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vaso-occlusive crises pipeline landscape is provided which includes the disease overview and Vaso-occlusive crises treatment guidelines. The assessment part of the report embraces, in depth Vaso-occlusive crises commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vaso-occlusive crises collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Vaso-occlusive crises. The therapies under development are focused on novel approaches to treat/improve Vaso-occlusive crises.

 

Vaso-occlusive crises Emerging Drugs

 

Inclacumab: Global Blood Therapeutics

Inclacumab is a novel, fully human monoclonal antibody P-selectin inhibitor for sickle cell disease patients with frequent pain crises, also known as vaso-occlusive crises (VOCs). P-selectin inhibition is clinically validated to reduce VOCs 1 a complication of sickle cell disease.

 

Global Blood Therapeutics has an exclusive worldwide licensing agreement with Roche for inclacumab, which has established pharmacokinetic data, safety and tolerability in more than 500 patients. Global Blood Therapeutics initiated two pivotal Phase III studies evaluating the effect of inclacumab on reducing the frequency of VOCs and on hospital readmissions for people with SCD. The THRIVE (Therapy for Reduction with Inclacumab of VOC Episodes) Studies are currently recruiting.

Further product details are provided in the report……..

Vaso-occlusive crises: Therapeutic Assessment

This segment of the report provides insights about the Vaso-occlusive crises drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Vaso-occlusive crises

There are approx. 5+ key companies which are developing the therapies Vaso-occlusive crises. The companies which have their Vaso-occlusive crises drug candidates in the most advanced stage, i.e Phase III include, Global Blood Therapeutics

 

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Vaso-occlusive crises pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

 

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vaso-occlusive crises: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vaso-occlusive crises therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vaso-occlusive crises drugs.

Vaso-occlusive crises Report Insights

• Vaso-occlusive crises Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vaso-occlusive crises Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vaso-occlusive crises drugs?
• How many Vaso-occlusive crises drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vaso-occlusive crises?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vaso-occlusive crises therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vaso-occlusive crises and their status?
• What are the key designations that have been granted to the emerging drugs?